Otrivin (Xylometazoline Hydrochloride)

Otrivin (xylometazoline) acts on the nasal mucosa to reduce swelling and improve airflow.

• Common cold: alleviates nasal congestion and promotes easier breathing.
• Acute sinusitis: reduces mucosal edema, helping drainage and symptom relief.
• Allergic rhinitis: decreases nasal passage swelling caused by allergens.
• Nasal congestion in children: provides short‑term relief of blockage in pediatric patients.

• Xylometazoline hydrochloride is a selective alpha‑adrenergic agonist that stimulates alpha‑1 and alpha‑2 receptors in the nasal mucosal blood vessels. This vasoconstriction reduces blood flow to the nasal lining, decreasing edema and opening the airway for improved breathing.

Side effects are generally mild and related to local irritation of the nasal mucosa.

Common Side Effects

• Burning or stinging sensation in the nose.
• Nasal dryness or crusting.
• Sneezing shortly after application.
• Mild headache.
• Transient epistaxis (nosebleed).

Serious or Rare Side Effects

• Persistent nasal irritation or ulceration.
• Severe or prolonged nosebleeds.
• Allergic reactions such as rash, itching, or swelling of the face.
• Rebound congestion with prolonged use (>5‑7 days).
• Hypertension exacerbation in susceptible individuals.

When using Otrivin, follow these safety considerations:

• Age restriction: not recommended for children under 2 years without medical advice.
• Duration limit: limit use to 3‑5 days to avoid rebound congestion.
• Pre‑existing conditions: use cautiously in patients with hypertension, heart disease, diabetes, or thyroid disorders.
• Pregnancy and lactation: consult a healthcare professional before use.
• Drug interactions: avoid concurrent use with other nasal decongestants.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Xylometazoline may interact with other medications that affect vascular tone or blood pressure.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): may potentiate hypertensive effects.
• Systemic sympathomimetics (e.g., pseudoephedrine): increased risk of hypertension.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: possible reduction in blood‑pressure‑lowering efficacy.
• Beta‑blockers: may blunt the vasoconstrictive response.
• Other topical nasal decongestants: risk of additive irritation and rebound congestion.
• Herbal supplements containing ephedra: potential synergistic vasoconstriction.